Celcuity Inc
CELC54.600USD
+1.530+2.88%
Cierre 09/17, 16:00（ET）Cotizaciones retrasadas 15 min
2.12BCap. mercado
PérdidaP/E TTM
Más Datos de Celcuity Inc Compañía
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Información de la empresa
Símbolo de cotizaciónCELC
Nombre de la empresaCelcuity Inc
Fecha de salida a bolsaSep 20, 2017
Director ejecutivoMr. Brian F. Sullivan
Número de empleados87
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 20
Dirección16305 36th Ave N Ste 100
CiudadMINNEAPOLIS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal55446-4285
Teléfono17633920767
Sitio Webhttps://www.celcuity.com/
Símbolo de cotizaciónCELC
Fecha de salida a bolsaSep 20, 2017
Director ejecutivoMr. Brian F. Sullivan
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.13M
+3.45%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.13M
+3.45%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 31 de ago
Actualizado: dom., 31 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
18.66%
BVF Partners L.P.
8.17%
Sullivan (Brian F)
7.38%
Soleus Capital Management, L.P.
7.10%
Perceptive Advisors LLC
6.29%
Otro
52.40%
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
18.66%
BVF Partners L.P.
8.17%
Sullivan (Brian F)
7.38%
Soleus Capital Management, L.P.
7.10%
Perceptive Advisors LLC
6.29%
Otro
52.40%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
42.18%
Investment Advisor
19.01%
Individual Investor
11.21%
Investment Advisor/Hedge Fund
7.74%
Venture Capital
6.52%
Private Equity
6.33%
Research Firm
2.10%
Corporation
0.82%
Pension Fund
0.08%
Otro
3.99%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
214
35.30M
87.21%
-4.75M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
2023Q1
152
18.61M
87.60%
-1.61M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baker Bros. Advisors LP
4.26M
11.24%
+1.58M
+58.96%
Mar 31, 2025
BVF Partners L.P.
3.47M
9.15%
--
--
Mar 31, 2025
Sullivan (Brian F)
3.02M
7.99%
+8.15K
+0.27%
Apr 14, 2025
Soleus Capital Management, L.P.
2.57M
6.8%
+9.04K
+0.35%
Mar 31, 2025
Perceptive Advisors LLC
2.36M
6.24%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.25M
3.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.03M
5.35%
+10.04K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
1.67M
4.42%
+20.26K
+1.23%
Mar 31, 2025
Eventide Asset Management, LLC
1.27M
3.34%
--
--
Mar 31, 2025
Laing (Lance G Ph.D.)
1.25M
3.3%
--
--
Mar 17, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
Innovator US Small Cap Managed Floor ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Avantis US Small Cap Equity ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Morningstar Small-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
SPDR S&P Biotech ETF
0%
Humankind US Stock ETF
0%
Ver más
Innovator US Small Cap Managed Floor ETF
Proporción0%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0%
iShares Morningstar Small-Cap ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
SPDR S&P Biotech ETF
Proporción0%
Humankind US Stock ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
